


Supplementary Figure S4



Single vs No Treatment											
	4:1	2:1	1:1								
PD-1	****	****	****	PD-1 + Lag-3				PD-1 alone			
PD-L1	****	****	**	PD-1 + Tim-3				PD-L1 alone			
Lag-3	ns	ns	ns	PD-L1 + Lag-3				Lag-3 alone			
Tim-3	**	ns	ns	PD-L1 + Tim-3				Tim-3 alone			
				Lag-3 + Tim-3				No Treatment			
Dual vs Single											
	4:1	2:1	1:1		4:1	2:1	1:1		4:1	2:1	1:1
PD-1+Lag-3 vs PD-1	ns	ns	ns	PD-L1+Lag-3 vs PD-L1	ns	ns	ns	Lag-3+Tim-3 vs Lag-3	ns	**	ns
PD-1+Lag-3 vs Lag-3	****	****	****	PD-L1+Lag-3 vs Lag-3	****	****	***	Lag-3+Tim-3 vs Tim-3	ns	ns	ns
PD-1+Tim-3 vs PD-1	****	*	ns	PD-L1+Tim-3 vs PD-L1	***	****	*				
PD-1+Tim-3 vs Tim-3	****	****	*	PD-L1+Tim-3 vs Tim-3	****	****	*				
Dual vs Dual											
	4:1	2:1	1:1		4:1	2:1	1:1		4:1	2:1	1:1
PD-1+Lag-3 vs PD-1+Tim-3	***	ns	ns	PD-1+Tim-3 vs PD-L1+Tim-3	ns	ns	ns				
PD-1+Lag-3 vs PD-L1+Lag-3	ns	ns	ns	PD-1+Tim-3 vs Lag-3+Tim-3	****	****	*				
PD-1+Lag-3 vs PD-L1+Tim-3	**	*	ns	PD-L1+Lag-3 vs PD-L1+Tim-3	***	****	ns				
PD-1+Lag-3 vs Lag-3+Tim-3	****	****	ns	PD-L1+Lag-3 vs Lag-3+Tim-3	****	***	ns				
PD-1+Tim-3 vs PD-L1+Lag-3	****	**	ns	PD-L1+Tim-3 vs Lag-3+Tim-3	****	****	**				

Supplementary Figure S4. Additive effect of different ICI combinations against NUGC3

Cytotoxic activity of CTL clones were assessed in different dual ICI treatment settings. Representative histograms of each inhibitory ligand expression are shown (top right). Comparison between combinations were analyzed and presented in table (bottom).